Cite
HARVARD Citation
Pollock, R. et al. (2019). A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of comparative effectiveness research. pp. 229-240. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pollock, R. et al. (2019). A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of comparative effectiveness research. pp. 229-240. [Online].